Subtopic Deep Dive

Peritoneal Carcinomatosis from Colorectal Cancer
Research Guide

What is Peritoneal Carcinomatosis from Colorectal Cancer?

Peritoneal carcinomatosis from colorectal cancer is the intraperitoneal dissemination of colorectal adenocarcinoma manifesting as multifocal peritoneal metastases.

Studies focus on Peritoneal Cancer Index (PCI) staging, cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC), and survival outcomes distinguishing synchronous from metachronous disease. Élias et al. (2009) analyzed 523 patients treated with CRS and perioperative intraperitoneal chemotherapy (PIC), reporting median survival of 30 months (981 citations). Jayne et al. (2002) characterized natural history and prognostic factors in colorectal peritoneal carcinomatosis (824 citations).

15
Curated Papers
3
Key Challenges

Why It Matters

Colorectal peritoneal carcinomatosis demands multimodality treatments distinct from hepatic metastases, with CRS + HIPEC improving survival over systemic chemotherapy alone. Élias et al. (2009) demonstrated 30-month median survival in 523 patients versus 12.6 months historically. Franko et al. (2011) showed systemic chemotherapy yields poor outcomes in peritoneal carcinomatosis colorectal cancer (pcCRC), with median survival of 15.3 months (578 citations). Quénet et al. (2021) PRODIGE 7 trial found no survival benefit from adding HIPEC to CRS, influencing treatment guidelines (738 citations).

Key Research Challenges

Optimal CRS + HIPEC Patient Selection

Identifying patients with low PCI and complete cytoreduction eligibility remains difficult due to heterogeneous disease burden. Jayne et al. (2002) identified histological grade and lymph node status as key prognosticators (824 citations). Élias et al. (2009) emphasized preoperative PCI assessment for 523 patients (981 citations).

Synchronous vs Metachronous Risk Stratification

Distinguishing prognostic implications of synchronous versus metachronous peritoneal metastases requires refined models. Sugarbaker and Jablonski (1995) reported superior outcomes in appendiceal versus colorectal primaries (581 citations). Chu et al. (1989) prospectively studied prognostic factors in 100 nongynecologic cases (595 citations).

HIPEC Morbidity and Long-term Efficacy

Balancing HIPEC toxicity against survival gains challenges clinical adoption post-PRODIGE 7. Quénet et al. (2021) phase 3 trial showed no OS benefit despite CRS feasibility (738 citations). Chua et al. (2012) documented long-term outcomes in appendiceal disease amenable to HIPEC (1029 citations).

Essential Papers

1.

Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Terence C. Chua, Brendan Moran, Paul H. Sugarbaker et al. · 2012 · Journal of Clinical Oncology · 1.0K citations

Purpose Pseudomyxoma peritonei (PMP) originating from an appendiceal mucinous neoplasm remains a biologically heterogeneous disease. The purpose of our study was to evaluate outcome and long-term s...

2.

Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French Study

Dominique Élias, François Noël Gilly, Florent Boutitie et al. · 2009 · Journal of Clinical Oncology · 981 citations

Purpose Peritoneal carcinomatosis (PC) from colorectal cancer traditionally is considered a terminal condition. Approaches that combine cytoreductive surgery (CRS) and perioperative intraperitoneal...

3.

Peritoneal carcinomatosis from colorectal cancer

David Jayne, Stephanie Fook, Carol Loi et al. · 2002 · British journal of surgery · 824 citations

Abstract Background Aggressive therapeutic regimens have been advocated for the treatment of peritoneal carcinomatosis from colorectal cancer. It is essential to understand the clinical and histolo...

5.

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum‐Gamez et al. · 2021 · Journal of the National Comprehensive Cancer Network · 681 citations

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country’s fifth most common cause of cancer mortality in women. A major challenge in ...

6.

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial

Xiaojun Yang, Chaoqun Huang, Tao Suo et al. · 2011 · Annals of Surgical Oncology · 675 citations

For synchronous gastric PC, CRS + HIPEC with mitomycin C 30 mg and cisplatin 120 mg may improve survival with acceptable morbidity.

7.

Peritioneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors

David Z. J. Chu, Nicholas P. Lang, C Thompson et al. · 1989 · Cancer · 595 citations

Regional recurrence of malignant tumors in the peritoneal cavity usually signifies a poor prognosis for the host and often results in gastrointestinal complications requiring surgical intervention....

Reading Guide

Foundational Papers

Start with Élias et al. (2009, 981 citations) for CRS+PIC outcomes in 523 patients; Jayne et al. (2002, 824 citations) for natural history and prognosticators; Sugarbaker and Jablonski (1995, 581 citations) for clinical features differentiating appendiceal/colorectal primaries.

Recent Advances

Quénet et al. (2021) PRODIGE 7 phase 3 trial showing no HIPEC benefit (738 citations); Chua et al. (2012) long-term pseudomyxoma peritonei survival data (1029 citations).

Core Methods

Peritoneal Cancer Index (PCI) staging; cytoreductive surgery (CRS) achieving completeness of cytoreduction (CC-0/1); hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C; retrospective/prospective cohort analyses and phase 3 RCTs.

How PapersFlow Helps You Research Peritoneal Carcinomatosis from Colorectal Cancer

Discover & Search

Research Agent uses citationGraph on Élias et al. (2009, 981 citations) to map French multicentric CRS+PIC studies, then findSimilarPapers reveals Sugarbaker and Jablonski (1995) prognostic features in 181 patients. exaSearch queries 'colorectal peritoneal carcinomatosis PCI staging models' surfaces 250M+ OpenAlex papers filtered by citations >500.

Analyze & Verify

Analysis Agent applies readPaperContent to extract PCI scores and survival data from Quénet et al. (2021) PRODIGE 7 trial, then runPythonAnalysis with pandas computes hazard ratios from Kaplan-Meier curves. verifyResponse (CoVe) cross-checks HIPEC efficacy claims against Jayne et al. (2002), achieving GRADE B evidence grading for prognostic factors.

Synthesize & Write

Synthesis Agent detects gaps in metachronous disease stratification between Élias et al. (2009) and Franko et al. (2011), flagging contradictions in systemic therapy outcomes. Writing Agent uses latexEditText to format PCI staging tables, latexSyncCitations integrates 10 key papers, and latexCompile generates review manuscript; exportMermaid visualizes CRS+HIPEC workflow diagrams.

Use Cases

"Extract survival data from colorectal PC trials and plot Kaplan-Meier curves"

Research Agent → searchPapers('colorectal peritoneal carcinomatosis survival') → Analysis Agent → readPaperContent(Élias 2009, Quénet 2021) → runPythonAnalysis(pandas/matplotlib KM plots) → researcher gets publication-ready survival curve figures with HR confidence intervals.

"Write LaTeX review on CRS+HIPEC patient selection criteria"

Synthesis Agent → gap detection(Élias 2009 vs PRODIGE 7) → Writing Agent → latexEditText(draft sections) → latexSyncCitations(10 core papers) → latexCompile → researcher gets compiled PDF with synchronized bibliography and PCI selection flowchart.

"Find code for PCI scoring calculator from colorectal PM papers"

Research Agent → paperExtractUrls(Jayne 2002) → paperFindGithubRepo → githubRepoInspect → Code Discovery workflow → researcher gets validated Python PCI calculator forked from cited surgical oncology repo.

Automated Workflows

Deep Research workflow conducts systematic review of 50+ colorectal PC papers via searchPapers + citationGraph, generating structured report ranking Élias (2009) and Chua (2012) by evidence strength. DeepScan 7-step analysis verifies PRODIGE 7 (Quénet 2021) HIPEC findings with CoVe checkpoints and runPythonAnalysis on trial data. Theorizer generates hypotheses on synchronous/metachronous stratification from Sugarbaker (1995) features.

Frequently Asked Questions

What defines peritoneal carcinomatosis from colorectal cancer?

Intraperitoneal dissemination of colorectal adenocarcinoma forming multifocal peritoneal metastases, staged by Peritoneal Cancer Index (PCI).

What are standard treatment methods?

Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) or perioperative intraperitoneal chemotherapy (PIC); Élias et al. (2009) reported 30-month median survival in 523 patients.

What are key papers?

Élias et al. (2009, 981 citations) multicentric CRS+PIC analysis; Jayne et al. (2002, 824 citations) natural history; Quénet et al. (2021, 738 citations) PRODIGE 7 phase 3 trial.

What are major open problems?

Optimal patient selection post-PRODIGE 7 negative HIPEC results; risk models distinguishing synchronous/metachronous disease; balancing CRS+HIPEC morbidity against survival gains.

Research Intraperitoneal and Appendiceal Malignancies with AI

PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:

See how researchers in Health & Medicine use PapersFlow

Field-specific workflows, example queries, and use cases.

Health & Medicine Guide

Start Researching Peritoneal Carcinomatosis from Colorectal Cancer with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Medicine researchers